Hinova Pharmaceuticals (SHSE:688302) Enterprise Value: ¥3,247.82 Mil (As of Jul. 07, 2026) ***


SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
24 GF Score
Price ¥37.85
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals Enterprise Value?

Hinova Pharmaceuticals SHSE:688302 -5.61% 24 Enterprise Value is ¥3,247.82 Mil as of Jul. 07, 2026. GuruFocus rates SHSE:688302 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hinova Pharmaceuticals's Enterprise Value is ¥3,247.82 Mil. Hinova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-134.81 Mil. Therefore, Hinova Pharmaceuticals's EV-to-EBIT ratio for today is -24.09.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Hinova Pharmaceuticals's Enterprise Value is ¥3,247.82 Mil. Hinova Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-134.81 Mil. Therefore, Hinova Pharmaceuticals's EV-to-EBITDA ratio for today is -24.09.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Hinova Pharmaceuticals's Enterprise Value is ¥3,247.82 Mil. Hinova Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥46.50 Mil. Therefore, Hinova Pharmaceuticals's EV-to-Revenue ratio for today is 69.85.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Hinova Pharmaceuticals's Enterprise Value is ¥3,247.82 Mil. Hinova Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-84.75 Mil. Therefore, Hinova Pharmaceuticals's EV-to-OCF ratio for today is -38.32.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Hinova Pharmaceuticals's Enterprise Value is ¥3,247.82 Mil. Hinova Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-149.21 Mil. Therefore, Hinova Pharmaceuticals's EV-to-FCF ratio for today is -21.77.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Hinova Pharmaceuticals  (SHSE:688302) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Hinova Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3247.820/-134.814
=-24.09

Hinova Pharmaceuticals's current Enterprise Value is ¥3,247.82 Mil.
Hinova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-134.81 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Hinova Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=3247.820/-134.814
=-24.09

Hinova Pharmaceuticals's current Enterprise Value is ¥3,247.82 Mil.
Hinova Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-134.81 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Hinova Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3247.820/46.495
=69.85

Hinova Pharmaceuticals's current Enterprise Value is ¥3,247.82 Mil.
Hinova Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥46.50 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Hinova Pharmaceuticals's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=3247.820/-84.751
=-38.32

Hinova Pharmaceuticals's current Enterprise Value is ¥3,247.82 Mil.
Hinova Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-84.75 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Hinova Pharmaceuticals's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3247.820/-149.21
=-21.77

Hinova Pharmaceuticals's current Enterprise Value is ¥3,247.82 Mil.
Hinova Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-149.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hinova Pharmaceuticals Enterprise Value Related Terms


Hinova Pharmaceuticals Enterprise Value Historical Data

* Premium members only.

The historical data trend for Hinova Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals Enterprise Value Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial 0.00 2,460.23 4,064.76 2,205.90 4,225.73

Hinova Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,454.54 3,884.52 4,570.60 4,225.73 3,635.98

SHSE:688302 vs VRTX, REGN, ALNY: Enterprise Value Comparison

For the Biotechnology subindustry, Hinova Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hinova Pharmaceuticals Enterprise Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's Enterprise Value falls into.


SHSE:688302
24GF Score
Hinova Pharmaceuticals Inc SHSE:688302
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Hinova Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Hinova Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of ¥3,247.82 Mil mean?
Hinova Pharmaceuticals (SHSE:688302) has a Enterprise Value of ¥3,247.82 Mil as of Jul. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Hinova Pharmaceuticals and its competitors.
Is Hinova Pharmaceuticals' Enterprise Value too high?
Hinova Pharmaceuticals' current Enterprise Value is ¥3,247.82 Mil. Overall, Hinova Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Enterprise Value compare to VRTX and REGN?
Hinova Pharmaceuticals' Enterprise Value of ¥3,247.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current Enterprise Value is ¥3,247.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Enterprise Value of ¥3,247.82 Mil. The current Enterprise Value is ¥3,247.82 Mil. Hinova Pharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Enterprise Value is ¥3,247.82 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
24GF Score

Get the complete analysis for SHSE:688302

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥37.85
Price